title: Bipolar therapeutics update 2014: A tale of 3 treatments.
authors: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Rd, Rm 2124, Stanford, CA 94305 tketter@stanford.edu.
authors: Terence A
authors: TA
authors: Ketter
authors: Po W
authors: PW
authors: Wang
authors: Shefali
authors: S
authors: Miller
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology*; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000494:pharmacology*; D001714:Bipolar Disorder / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000494:pharmacology*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors*; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D054833:Isoindoles / Q000009:adverse effects / Q000494:pharmacology*; D000069056:Lurasidone Hydrochloride; D000077408:Modafinil; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology*; D013844:Thiazoles / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D001559:Benzhydryl Compounds; D018491:Dopamine Agonists; D050483:Dopamine Plasma Membrane Transport Proteins; D054833:Isoindoles; D010879:Piperazines; D013844:Thiazoles; C533287:cariprazine; D000069056:Lurasidone Hydrochloride; D000077408:Modafinil